Global PD-1 and PD-L1 Inhibitors Market Report and Forecast 2024-2032

Global PD-1 and PD-L1 Inhibitors Market Outlook

The global PD-1 and PD-L1 inhibitors market size was valued at USD 45.8 billion in 2023, driven by increasing incidence of cancer cases across the globe. The market is expected to grow at a CAGR of 17.96% during the forecast period of 2024-2032, with the values likely to attain USD 202.5 billion by 2032.

PD-1 and PD-L1 Inhibitors: Introduction

PD-1 and PD-L1 inhibitors are checkpoint inhibitors used to block the activity of PD-1 and PDL1 immune checkpoint proteins, commonly present on the surface of cells. These inhibitors play a pivotal role in offering immunotherapy to cancer patients. The interaction of these cell surface proteins is also engaged in the immune system suppression and occurs following infection to restrain the killing of bystander host cells and avoid autoimmune disease.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global PD-1 and PD-L1 Inhibitors Market Analysis

The growing incidence of cancer has propelled deeper research into various types of therapies that could be found useful in offering treatment alternatives to patients. There is heightened focus on immunotherapy, owing to the rising requirements of personalized medicine in patients. Consequently, the PD-1 and PD-L1 inhibitors market demand has seen significant upswing in recent years.

Over the years, PD-1 inhibiotrs like Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo) and PD-L1 inhibitors Atezolizumab (Tecentriq), Avelumab (Bavencio) and Durvalumab (Imfinzi) have been the most used inhibitors in the market. However, with a better understanding the human physiology and increased technical advancements, innovations keep emerging in the market. For instance, in March 2023, the FDA approved Incyte’s intravenous drug, Zynyz, which can be used to treat metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

In addition, new technologies have been introduced to improve the quality and efficacy of drugs further. In November 2023, a liquid biopsy company called Angle that offers circulating tumour cell diagnostic solutions launched its Portrait PD-L1 test. This test works to evaluate the protein expression of PD-L1 on CTCs. Therefore, the PD-1 and PD-L1 inhibitors market value is anticipated to grow further during the forecast period.

Global PD-1 and PD-L1 Inhibitors Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Type

• PD-1 Inhibitors

• PD-L1 Inhibitors

Market Breakup by Application

• Hodgkin Lymphoma

• Kidney Cancer

• Melanoma

• Non-Small Cell Lung Cancer

• Other Applications

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global PD-1 and PD-L1 Inhibitors Market Overview

In the forecast period, North America is predicted to possess a significant PD-1 and PD-L1 inhibitors market share. This can be attributed to the rising technical advancements and the existence of a well-equipped healthcare infrastructure to integrate the new age advancements. The presence of prominent MedTech companies and research institutions is another major factor driving the market. Similarly, Europe with a robust healthcare ecosystem is a significant player in the market. The region also focuses on educating and training the medical staff to function well with all the rising innovation.

The Asia Pacific region, on the other hand, is projected to witness rapid PD-1 and PD-L1 inhibitors market growth. Given the increasing adoption of new technologies to improve the medical ecosystem and foster innovation, the region is continuously growing and developing for better patient care. The presence of an aging population is driving development. In addition, there is a significant influx of international investments, with several key healthcare players setting up new and high-end research labs in the region to leverage the academic talent available.

Global PD-1 and PD-L1 Inhibitors Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Bristol Myers Squibb

• Merck & Co., Inc.

• Roche

• AstraZeneca

• Pfizer, Inc.

• Eli Lilly and Company

• Sanofi

• Regeneron Pharmaceuticals

• Novartis AG

• BIOCAD

• Cipla Limited

• MacroGenics, Inc.

• Innovent Biologics

• Jiangsu Hengrui Medicine Co., Ltd.

• Mirati Therapeutics

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report